Skip to main content
. Author manuscript; available in PMC: 2020 Dec 22.
Published in final edited form as: Mol Pharm. 2015 Oct 2;12(11):3986–3998. doi: 10.1021/acs.molpharmaceut.5b00432

Figure 11.

Figure 11.

Versatility and scalability of DBM linkers. (A) HIC traces of ADCs derived from conjugation of 2 (DBM-MMAF) with 3 different commercially available antibodies: Avastin, Rituxan, and Erbitux. (B) HIC traces of ADCs resulting from conjugation of 2 with IGNX at 3 different reaction scales (1 mg, 25 mg, and 1000 mg).